The CRC Digest

Curated CRC research — accessible, accurate, actionable

Thursday, March 12, 2026

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

• Anti-EGFR therapy shows comparable survival regardless of treatment line in left-sided metastatic colorectal cancer

  A retrospective study found that anti-EGFR monoclonal antibodies provided similar survival benefits whether given as first-line or later-line treatment in patients with RAS wild-type left-sided metastatic colorectal cancer, suggesting timing flexibility may exist for this therapy. (Journal of Gastrointestinal Oncology)

• Early-onset colorectal cancer rising in Argentina, with more advanced stages at diagnosis

  A multicenter surgical analysis of 19,373 patients found that early-onset colorectal cancer (diagnosed before age 50) is increasing in Argentina and is associated with more advanced tumor stages and higher rates of lymph node involvement and metastasis compared to later-onset disease. (The Lancet Regional Health – Americas)

• Tumor Jagged1 expression may predict bevacizumab response in metastatic colorectal cancer

  Researchers identified tumor Jagged1 expression as a potential biomarker for predicting which metastatic colorectal cancer patients may benefit from bevacizumab combined with 5-fluorouracil chemotherapy, addressing a current gap in personalized treatment selection. (Gastroenterology Report)

• Gut microbiome shows decreased vitamin K pathway function in colorectal adenoma patients

  A metagenomic study found that patients with colorectal adenomas—precancerous polyps—have reduced menaquinone (vitamin K2) pathway functions in their gut microbiome compared to those without adenomas, suggesting early microbial changes may occur before cancer develops. (PLOS ONE)

These findings continue to refine our understanding of colorectal cancer biology, treatment timing, and early detection strategies.

The CRC Digest

Research Intelligence for the Colorectal Cancer Community

Content is curated with AI assistance and reviewed by the editorial team.

Read our full disclaimer

Unsubscribe